Abbott gets nod for Xience Prime

Based on data from the SPIRIT family of trials, the FDA has given its OK for Abbott's ($ABT) next-generation Xience Prime everolimus-eluting stent system for the treatment of coronary artery disease.

Abbott says Xience Prime features a delivery system designed for greater flexibility and more accurate stent placement.

"With Xience Prime, for the first time in the U.S., physicians have a 38 mm everolimus-eluting stent for the treatment of long lesions. The enhanced deliverability and wide range of sizes, including a small-vessel 2.25 mm-diameter stent, will improve our ability to access challenging, complex lesions, and thereby improve care for our patients," explains Marco Costa, principal investigator of the global SPIRIT PRIME trial.

The system received CE Mark in 2009. It is now available in the U.S., Europe, the Middle East and most of Asia, according to an Abbott release.

As Mass Device notes, the clearance marks the latest round in the so-called stent wars between Abbott, Boston Scientific ($BSX) and Medtronic ($MDT).

- check out the Abbott statement
- get more from Mass Device

ALSO: Researchers are slated to discuss a flaw that causes drug-coated heart stents to weaken and shrink. The flaw, known as longitudinal compression, was added to the agenda at the Transcatheter Cardiovascular Therapeutics meeting that starts next week in San Francisco. News

Suggested Articles

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.